This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional regarding any personal health concern, including erectile dysfunction. ED may be a symptom of an underlying cardiovascular or metabolic condition — clinical evaluation is appropriate when symptoms are new, worsening, or accompanied by other cardiovascular signs.
By VFM Research Desk | Last verified: May 2026
Quick Answer: Erectile function depends on coordinated signaling across three systems: vascular (blood flow driven by nitric oxide and the PDE5 pathway), neurological (brain-to-body arousal signals through dopamine and related pathways), and hormonal (testosterone supporting baseline desire and tissue responsiveness). ED becomes clinically significant when dysfunction is consistent rather than situational. An estimated 30 million men in the US are affected. Cardiovascular fitness, metabolic health, sleep quality, and psychological state are the four lifestyle variables that consistently appear in the research as primary modifiable contributors. Prescription treatment addresses one or more of these pathways depending on the formulation.
You notice it for the first time and assume it was the alcohol, or the stress, or an off night. Then it happens again, and the explanation feels less convincing. By the time most men start searching for information, they have already cycled through several months of situational explanations — and the pattern has become impossible to dismiss.
ED affects an estimated 30 million men in the United States. Prevalence increases substantially with age: roughly 40% of men at age 40, rising to approximately 70% by age 70 in population studies. Understanding why it happens is the foundation for evaluating what, if anything, to do about it.
Why Erectile Function Matters Beyond the Obvious
In most men under 60, new-onset erectile dysfunction is a cardiovascular warning signal — not simply a sexual health issue. ED is frequently the first visible sign of cardiovascular disease, metabolic dysfunction, or hormonal dysregulation, appearing years before more overt symptoms in some men. The vascular mechanism underlying normal erectile function requires the same endothelial health and arterial flexibility that supports heart and brain circulation. When that system is compromised, erectile function often shows it first because the penile vasculature is smaller and more sensitive to endothelial dysfunction than larger cardiovascular vessels.
This is why clinical guidance from the American Urological Association and American Heart Association recommends that new-onset ED in men with cardiovascular risk factors be evaluated for underlying cardiovascular disease before the ED is treated in isolation. Reaching for a telehealth prescription before that evaluation has happened is, in many cases, treating the symptom while the underlying condition goes unaddressed.
The Biological Mechanism Behind Erectile Function
A normal erection is the result of coordinated signaling across three physiological systems — vascular, neurological, and hormonal — working simultaneously. Disruption at any point in the sequence can produce dysfunction.
The neurological trigger comes first. Sexual arousal — whether psychogenic (mental/sensory) or reflexogenic (direct physical stimulation) — activates parasympathetic nerve signals from the brain and spinal cord that reach penile tissue. These signals trigger the release of nitric oxide (NO) from the endothelium and nerve terminals in the corpus cavernosum.
Nitric oxide then activates guanylyl cyclase, which converts GTP to cyclic GMP (cGMP). Elevated cGMP causes smooth muscle relaxation in the arterial walls of the corpus cavernosum, allowing blood to flow in rapidly. The resulting pressure compresses venous drainage, trapping blood and producing the sustained pressure of an erection. This is the core vascular-erectile mechanism.
Phosphodiesterase type 5 (PDE5) breaks down cGMP, terminating the response. This is precisely the mechanism that PDE5 inhibitors — sildenafil, tadalafil, vardenafil — target. They do not create arousal or produce erections on their own. They slow cGMP breakdown so that when arousal initiates the signaling chain, the vascular response is more complete and sustained.
The dopamine system runs in parallel. Central dopamine pathways — particularly in the hypothalamus and limbic system — regulate arousal, motivation, and the initiation of the erectile response from the brain’s side. This is the pathway apomorphine targets. Men whose ED has a significant desire-related or neurological component alongside the vascular issue may not achieve adequate results from PDE5 inhibitor therapy alone, because that class only addresses the downstream vascular half of the equation.
What the Research Says About ED Causes
The research is consistent: ED is predominantly vascular in men over 40, with neurogenic, hormonal, and psychogenic factors playing larger roles in younger men and frequently coexisting across all age groups.
Vascular causes — endothelial dysfunction, arterial stiffness, reduced nitric oxide bioavailability — account for the majority of organic ED cases. The same cardiovascular risk factors that drive coronary artery disease (smoking, hypertension, diabetes, hyperlipidemia, physical inactivity) directly compromise penile vascular function. A meta-analysis published in the Journal of Sexual Medicine found that ED is an independent predictor of major adverse cardiovascular events, with a hazard ratio comparable in magnitude to traditional cardiovascular risk factors. (Source: PubMed — Journal of Sexual Medicine, 2019.)
Neurogenic causes include spinal cord injury, multiple sclerosis, radical prostatectomy, pelvic surgery, and diabetic neuropathy — all conditions that disrupt the nerve signaling component of the erectile pathway. Psychological causes, including performance anxiety, depression, and relationship factors, operate through central dopamine and norepinephrine pathway disruption and are frequently concurrent with organic causes rather than purely separate.
Hormonal factors — primarily testosterone — support baseline sexual desire, penile tissue responsiveness, and nitric oxide synthase activity. Hypogonadism alone rarely causes complete organic ED in isolation, but it substantially raises the threshold at which vascular and neurological factors become symptomatic. Men with borderline testosterone who respond inadequately to PDE5 inhibitors alone may have a hormonal component worth evaluating — addressed in the Testosterone Supplements vs TRT guide on this site.
Lifestyle Variables That Affect Erectile Function
Four modifiable lifestyle variables consistently appear in the research as primary contributors to ED risk and severity — and addressing them often improves function independently of any medication.
Cardiovascular fitness is the strongest modifiable predictor in the evidence base. A meta-analysis in the Journal of Sexual Medicine covering randomized controlled trials found that aerobic exercise training significantly improved erectile function scores, with the largest effect in men with cardiovascular risk factors. (Source: PubMed — Journal of Sexual Medicine, 2018.) The mechanism is direct: aerobic exercise improves endothelial function and nitric oxide bioavailability — the same vascular system erectile function depends on.
Metabolic health — specifically insulin sensitivity and body composition — is the second major modifiable variable. Type 2 diabetes damages both the vascular endothelium and peripheral nerve function, disrupting the erectile pathway at multiple points. Multiple trials have shown that weight reduction in obese men improves erectile function independently of medication.
Sleep quality is underappreciated. Testosterone synthesis peaks during deep sleep, and obstructive sleep apnea is independently associated with ED in multiple epidemiological studies. Men with significant snoring, daytime fatigue, or witnessed apnea who also experience ED have a meaningful probability that a sleep disorder is contributing to both problems through the hormonal pathway.
Psychological state and stress load operate through the central dopamine and norepinephrine systems. Chronic stress elevates sympathetic tone, which works directly against the parasympathetic activation that initiates the erectile response. Performance anxiety — the fear of recurrence after one or more failed attempts — creates a self-reinforcing loop where anticipatory sympathetic activation prevents the very response the man is anxious about producing. This is the mechanism through which a primarily vascular problem can become partially psychogenic over time.
Where Supplements Fit
Non-prescription supplements targeting erectile function work primarily through the nitric oxide pathway — supporting upstream substrate availability, not PDE5 inhibition. L-arginine and L-citrulline are amino acid precursors to nitric oxide synthesis. The evidence for L-citrulline supplementation improving mild to moderate erectile function is consistent across small to medium randomized trials, with a study published in Urology showing improvement in erection hardness scores at 1.5g/day (Cormio et al., PubMed DOI: 10.1016/j.urology.2010.08.028). This represents a categorically different mechanism and effect size than PDE5 inhibitor therapy.
The L-arginine and nitric oxide mechanism is covered in detail in the L-Arginine, L-Citrulline, and Nitric Oxide guide on this site. That evidence base is relevant for men with mild vascular ED who want to optimize their nutritional foundation before or alongside any prescription approach.
Prescription treatment options — from single-ingredient PDE5 inhibitors through standard telehealth platforms to compounded multi-ingredient formulations for men who have exhausted that tier — are reviewed in the Best ED Telehealth Platforms guide. For a detailed breakdown of how each PDE5 inhibitor works pharmacologically, read PDE5 Inhibitors Explained.
When to Seek Clinical Evaluation
New-onset consistent ED in a man under 60 is a prompt for a physician visit — not just a trigger to search for supplements or sign up for a telehealth prescription. The recommendation from the AUA and AHA is that new ED in men with cardiovascular risk factors be evaluated for underlying cardiovascular disease before the ED is treated in isolation.
Appropriate evaluation includes a fasting lipid panel, fasting glucose and HbA1c, blood pressure, and morning total and free testosterone if symptoms suggest hypogonadism. These are standard metabolic markers a primary care physician can order. Starting a PDE5 inhibitor without this baseline evaluation is not dangerous for most men, but it means potentially treating a symptom while the underlying condition — early cardiovascular disease, undiagnosed diabetes, hypogonadism — goes unaddressed.
Men taking any nitrate medication for chest pain, heart failure, or any cardiac indication must not use any PDE5 inhibitor without explicit guidance from their cardiologist. The interaction is serious and well-documented. The full drug interaction profile for ED medications is covered in the ED Medication Safety Guide on this site.
This article is for informational purposes only and does not constitute medical advice. Individual health circumstances vary. A qualified healthcare professional should evaluate all relevant health history before any prescription treatment is considered. Dietary supplements are not FDA-evaluated or approved to diagnose, treat, cure, or prevent any disease. Individual results vary.
Leave a Reply